title: SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation.
abstract: Methamphetamine (METH) abuse is associated with several negative side effects including neurotoxicity in specific brain regions such as the striatum. The precise molecular mechanisms by which METH usage results in neurotoxicity remain to be fully elucidated, with recent evidence implicating the importance of microglial activation and neuroinflammation in damaged brain regions. METH interacts with sigma receptors which are found in glial cells in addition to neurons. Moreover, sigma receptor antagonists have been shown to block METH-induced neurotoxicity in rodents although the cellular mechanisms underlying their neuroprotection remain unknown. The purpose of the current study was to determine if the prototypic sigma receptor antagonist, SN79, mitigates METH-induced microglial activation and associated increases in cytokine expression in a rodent model of METH-induced neurotoxicity. METH increased striatal mRNA and protein levels of cluster of differentiation 68 (CD68), indicative of microglial activation. METH also increased ionized calcium binding adapter molecule 1 (IBA-1) protein expression, further confirming the activation of microglia. Along with microglial activation, METH increased striatal mRNA expression levels of IL-6 family pro-inflammatory cytokines, leukemia inhibitory factor (lif), oncostatin m (osm), and interleukin-6 (il-6). Pretreatment with SN79 reduced METH-induced increases in CD68 and IBA-1 expression, demonstrating its ability to prevent microglial activation. SN79 also attenuated METH-induced mRNA increases in IL-6 pro-inflammatory cytokine family members. The ability of a sigma receptor antagonist to block METH-induced microglial activation and cytokine production provides a novel mechanism through which the neurotoxic effects of METH may be mitigated.
authors: Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, 1 Medical Center Dr., West Virginia University Health Sciences Center, Morgantown, WV 26506, USA.
authors: Matthew J
authors: MJ
authors: Robson
authors: Ryan C
authors: RC
authors: Turner
authors: Zachary J
authors: ZJ
authors: Naser
authors: Christopher R
authors: CR
authors: McCurdy
authors: Jason D
authors: JD
authors: Huber
authors: Rae R
authors: RR
authors: Matsumoto
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D001583:Benzoxazoles / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D017628:Microglia / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology*; D012333:RNA, Messenger; D017480:Receptors, sigma / Q000037:antagonists & inhibitors*; D013997:Time Factors; D015854:Up-Regulation / Q000187:drug effects*; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D001583:Benzoxazoles; D016207:Cytokines; D008694:Methamphetamine; D010879:Piperazines; D012333:RNA, Messenger; D017480:Receptors, sigma; C557789:6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo(d)oxazol-2(3H)-one; C067980:CD68 antigen, human; D000097382:CD68 Molecule
keywords: Cytokine; Methamphetamine; Microglial activation; Neurotoxicity; Sigma receptor
references: Ann N Y Acad Sci. 2006 Aug;1074:31-41
references: 17105901
references: J Neurosci. 2001 Dec 1;21(23):9414-8
references: 11717374
references: Glia. 2009 May;57(7):744-54
references: 19031439
references: Eur Neuropsychopharmacol. 2008 Dec;18(12):871-81
references: 18755577
references: Pharmacotherapy. 2006 Aug;26(8):1148-56
references: 16863490
references: J Neurosci Res. 2005 Aug 1;81(3):342-8
references: 15957187
references: Int J Neuropsychopharmacol. 2013 Jun;16(5):1033-44
references: 22932447
references: Mov Disord. 2010 Oct 30;25(14):2333-9
references: 20737543
references: Brain Res Rev. 2009 May;60(2):379-407
references: 19328213
references: J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
references: 15163680
references: Blood. 2010 Jun 10;115(23):4951-62
references: 20354174
references: Brain Res. 1998 Dec 14;814(1-2):120-6
references: 9838075
references: Mol Pharmacol. 2012 Mar;81(3):299-308
references: 22101517
references: Mol Psychiatry. 2012 Sep;17(9):918-25
references: 21747399
references: Curr Pharm Des. 2012;18(7):902-19
references: 22288407
references: Psychopharmacology (Berl). 2008 Feb;196(2):233-41
references: 17909751
references: PLoS One. 2012;7(9):e45118
references: 23028794
references: Nat Rev Immunol. 2008 Dec;8(12):958-69
references: 19029990
references: Neuropharmacology. 2000 Jan 28;39(3):399-406
references: 10698006
references: Expert Opin Investig Drugs. 2012 Feb;21(2):169-78
references: 22233449
references: Neurosurgery. 2009 Jul;65(1):179-85; discussion 185-6
references: 19574840
references: Brain Res. 2012 Jun 21;1461:102-10
references: 22583855
references: J Pharmacol Exp Ther. 2012 Jun;341(3):663-71
references: 22399814
references: Gen Hosp Psychiatry. 2010 Sep-Oct;32(5):559.e1-3
references: 20851278
references: Neuropharmacology. 2005 Oct;49(5):638-45
references: 15939443
references: J Neurosci. 2008 May 28;28(22):5756-61
references: 18509037
references: Neurosci Lett. 2010 Sep 13;481(3):144-8
references: 20600592
references: Int Rev Neurobiol. 2009;88:101-19
references: 19897076
references: J Pharmacol Exp Ther. 2011 Oct;339(1):161-72
references: 21715561
references: Biol Psychiatry. 2007 Mar 1;61(5):577-81
references: 16712806
references: Eur Neuropsychopharmacol. 2013 Aug;23(8):960-71
references: 22921523
references: J Pharmacol Exp Ther. 2005 Nov;315(2):658-67
references: 16076935
references: Immunology. 1996 Jul;88(3):389-93
references: 8774355
references: Ann N Y Acad Sci. 2008 Oct;1139:103-11
references: 18991854
references: Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93
references: 16839653
references: Ann N Y Acad Sci. 2008 Oct;1139:318-30
references: 18991877
references: Dev Neurosci. 2011;33(3-4):199-209
references: 21757877
references: Nat Rev Neurol. 2010 Apr;6(4):193-201
references: 20234358
references: Neurosci Lett. 2004 Sep 9;367(3):349-54
references: 15337264
references: J Clin Exp Hematop. 2011;51(2):93-9
references: 22104307
references: Am J Psychiatry. 2001 Mar;158(3):377-82
references: 11229977
references: J Pharmacol Exp Ther. 1995 Jan;272(1):224-30
references: 7815336
references: Mol Pharmacol. 2000 Dec;58(6):1247-56
references: 11093760
references: Exp Neurol. 2004 May;187(1):47-57
references: 15081587
references: Curr Neurovasc Res. 2006 May;3(2):89-98
references: 16719792
references: Curr Drug Abuse Rev. 2010 Sep;3(3):156-62
references: 21054260
references: Drug Alcohol Depend. 2012 Jan 1;120(1-3):35-40
references: 21794992
references: J Neurochem. 2012 Sep;122(5):995-1009
references: 22776046
references: Cell. 2007 Nov 2;131(3):596-610
references: 17981125
references: AAPS J. 2011 Sep;13(3):336-46
references: 21494909
references: Brain Res Bull. 2012 Jan 4;87(1):10-20
references: 22024597
references: Neuropharmacology. 2011 Oct-Nov;61(5-6):992-1000
references: 21762711
references: J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):415-421
references: 22684568
references: J Neurochem. 2005 Feb;92(4):790-7
references: 15686480
references: Nat Rev Immunol. 2011 Oct 25;11(11):775-87
references: 22025055
references: Pharmacol Biochem Behav. 2011 Mar;98(1):12-20
references: 21130800
references: Pathol Int. 2010 Apr;60(4):278-83
references: 20403029
references: Addiction. 2009 Jul;104(7):1085-99
references: 19426289
references: Ann N Y Acad Sci. 2000 Sep;914:238-62
references: 11085325
references: FASEB J. 2003 Oct;17(13):1775-88
references: 14519657
references: J Pharmacol Exp Ther. 1994 Mar;268(3):1571-80
references: 8138969